Amarin Reports First Quarter 2020 Financial Results and Provides Update on Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amarin Corporation (AMRN) PT Raised to $8 at Jefferies
April 30, 2020 12:26 PM EDTJefferies analyst Michael Yee raised the price target on Amarin Corporation (NASDAQ: AMRN) to $8.00 (from $7.00) while maintaining a Hold rating.
... MoreAmarin Corp. (AMRN) Tops Q1 EPS by 1c, Revenues Beat
April 30, 2020 5:41 AM EDTAmarin Corp. (NASDAQ: AMRN) reported Q1 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $155 million versus the consensus estimate of $137.43 million.
Key recent Amarin achievements include:
Record revenue: Net total revenue reached a record high of $155.0 million in Q1 2020 as compared to $73.3 in Q1 2019, an increase of approximately 112% primarily reflecting increased VASCEPA® (icosapent ethyl) prescription growth in the United States augmented by $6.7 million net product revenue from VASCEPA sales outside of the United States.Commercial expansion: Increased size of U.S. sales force for... More